Xonvea Magasýruþolin tafla 10 mg/10 mg Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

xonvea magasýruþolin tafla 10 mg/10 mg

campuspharma ab - pyridoxinum hýdróklóríð; doxylaminii hýdrógen súkkínat - magasýruþolin tafla - 10 mg/10 mg

Chanazine 10%, vet. Stungulyf, lausn 10 % Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

chanazine 10%, vet. stungulyf, lausn 10 %

chanelle pharmaceuticals manufacturing ltd* - xylazinum inn - stungulyf, lausn - 10 %

Chanazine 2%, vet. Stungulyf, lausn 2 % Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

chanazine 2%, vet. stungulyf, lausn 2 %

chanelle pharmaceuticals manufacturing ltd* - xylazinum inn - stungulyf, lausn - 2 %

Rompun vet. Stungulyf, lausn 20 mg/ml Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

rompun vet. stungulyf, lausn 20 mg/ml

elanco animal health gmbh - xylazinum hýdróklóríð - stungulyf, lausn - 20 mg/ml

Wakix Unió Europea - islandès - EMA (European Medicines Agency)

wakix

bioprojet pharma - pitolisant - narcolepsy - Önnur lyf í taugakerfinu - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.

Ozawade Unió Europea - islandès - EMA (European Medicines Agency)

ozawade

bioprojet pharma - pitolisant - sleep apnea, obstructive - Önnur lyf í taugakerfinu - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).